Related references
Note: Only part of the references are listed.Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo
Lijing Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy
Jenny Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
Jared A. Gollob et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Growth inhibitory effects of pegylated IFN α-2b on human liver cancer cells in vitro and in vivo
Hirohisa Yano et al.
LIVER INTERNATIONAL (2006)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma
Y Sakaguchi et al.
INTERVIROLOGY (2005)
Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma
S Nishiguchi et al.
INTERVIROLOGY (2005)
Interferon-αCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo
T Hisaka et al.
JOURNAL OF HEPATOLOGY (2004)
Combined Intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches
M Sakon et al.
CANCER (2002)
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer
K Ikeda et al.
HEPATOLOGY (2000)
Share Paper
